World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030
- PDF / 573,739 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 159 Views
RESEARCH
Open Access
World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal Birama Diarra1,2†, Albert Theophane Yonli1,2†, Abdoul Karim Ouattara1,2* , Theodora Mahoukèdè Zohoncon1,2, Lassina Traore1,2, Christelle Nadembega2, Dorcas Obiri-Yeboah3, Justine Yara4,5, Virginio Pietra1, Paul Ouedraogo5, Alain Bougouma6, Rokia Sanogo7 and Jacques Simpore1,2,5
Abstract Background: Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. Methods: Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the “SOS Hepatitis Burkina” association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. Results: In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. Conclusions: This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. Trial registration: The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015. Keywords: Hepatitis B, Awareness, Screening, Vaccination
Background Hepatitis B, caused by the hepatitis B virus (HBV), is a major cause of liver disease morbidity and mortality worldwide [1]. Chronic HBV infection can cause liver cirrhosis and hepatocellular carcinoma (HCC) [2]. The World Health * Correspondence: [email protected] † Birama Diarra and Albert Theophane Yonli contributed equally to this work. 1 Biomolecular Research Center Pietro Annigoni (CERBA), BP 364, Ouagadougou 01, Burkina Faso 2 Laboratory of Molecular Biology and Molecular Genetics (LaBioGene) UFR/ SVT, University Ouaga I Prof Joseph KI-ZERBO, BP 7021, Ouagadougou 03, Burkina Faso Full list of author information is available at the end of the article
Organization (WHO) estimates an about two billion people are infected with this virus around the world and more than 360 million cases of chronic infections. About 686,000 deaths each year are attributed to the consequences of HBV infection [1]. HBV is transmitted parenterally via apparent percutaneous or per-mucous expos
Data Loading...
